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A short peptide that preferentially binds c-MYC G-quadruplex 
DNA 
Aisling Minard,a,d,† Danielle Morgan,b,†  Federica Raguseo,a Anna Di Porzio,a,c Denise Liano,a,d  
Andrew Jamieson*b and Marco Di Antonio,*a,d
G-quadruplexes (G4s) are non-canonical DNA secondary structures. 
The identification of selective tools to probe individual G4s over the 
~700,000 found in the human genome is key to unravel the 
biological significance of specific G4s. We took inspiration from a 
crystal structure of the bovine DHX36 helicase bound to the G4 
formed in the promoter region of the oncogene c-MYC to identify a 
short peptide that preferentially binds MYC G4 with nM affinity  
over a small panel of parallel and antiparallel G4s tested.
Besides the well-known double-helical structure, DNA can 
adopt several non-canonical structural arrangements under 
physiological conditions.1 G-quadruplexes (G4s) have recently 
emerged as an interesting alternative DNA structure with 
respect to their potential for biological regulation. Sequences 
that form G4s are highly abundant, with more than 700,000 G4-
structures experimentally detected across the human genome 
by sequencing experiments.2 Because of their high genomic 
prevalence, DNA G4s have been speculated to play a role in 
several biological processes, including transcriptional 
regulation,3 telomeric maintenance,4 genomic instability,5 
cancer progression,3 accelerating ageing6 and 
neurodegenerative diseases.7 To this end, several tools to map, 
visualise and stabilise G4s in biologically relevant contexts have 
been developed, in an attempt to unravel the specific biological 
roles played by G4-formation in cells.8 Although genome-wide 
mapping experiments by means of Chromatin Immuno-
Precipitation (ChIP) methods have facilitated the detection of 
G4s that are actually formed in cells,9 the investigation of 
biological consequences regulated by G4-stabilisation mainly 
relies on the use of small-molecule ligands that can be applied 
in living cells and monitored in real-time. To date, several 
ligands with high affinity and specificity for G4s over canonical 
double-stranded DNA have been reported.10 Small-molecule 
targeting approaches mainly rely on - stacking interactions of 
the molecular probes with the top (or bottom) end of the G4-
structure. Whilst this approach is highly effective to achieve G4 
vs duplex selectivity, it is less applicable to achieve selectivity 
towards a small subset of G4s over the ~700,000 available in the 
human genome. This is most likely due to the promiscuous 
presence of accessible -stacking surfaces across different G4-
structures, which hampers selective recognition of an individual 
G4 by means of - stacking interactions alone.
Here, we have taken inspiration from a recently reported crystal 
structure of the bovine DHX36 helicase bound to the G4-
structure formed in the promoter region of the oncogene c-
MYC11 to identify a short-peptide sequence (DM039) that binds 
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Figure 1: (A) Minimal peptide binding domain of DHX36 
bound to the MYC DNA G-quadruplex. (B) The 22-amino 
acid sequence (DM039) used in this study. 
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with nM affinity the MYC G4. Interestingly, DM039 showed 
negligible binding to other G4-forming sequences of parallel, 
antiparallel and mixed type topologies, suggesting potential for 
selective targeting of MYC. Furthermore, we found that when 
constrained into a helical conformation by hydrocarbon 
stapling, the peptide displayed lower binding affinity to MYC 
and loss of selectivity towards double and single stranded DNA. 
This data suggested that the peptide requires a good degree of 
structural flexibility for high affinity and selective G4-binding, 
which is not intuitive based on the helical conformation 
adopted by the peptide in the crystal structure.11 
We started our investigation analysing the crystal structure of 
the bovine DHX36 bound to MYC G411 (PDB ID: 5VHE) using 
PyMOL12 (Figure 1A) and identified the 22-amino acid sequence 
reported in Figure 1B as the minimal MYC-binding domain of the 
protein in this particular context. This 22 amino acid sequence 
(Figure 1B) is in agreement with that previously reported by 
NMR studies on the human version of the DHX36 helicase, 
which identified similar sequences (18, 23, 29 and 53 amino 
acids) as G4-binding motifs.13 We then synthesised the 22-
amino acids sequence (DM039) to investigate whether this 
particular peptide motif displayed an increased selectivity 
towards MYC G4 over other G4-structures. DM039 was 
synthesised using previously established Fmoc/tBu solid-phase 
peptide synthesis (SPPS) protocols, employing an automated 
SPPS synthesiser, and acetylated at the N-terminal prior HPLC 
purification and MS characterisation (see ESI).
We next sought to evaluate the binding affinity of DM039 
towards a small panel of G4-forming sequences as well as a 
single-stranded and a double-stranded control sequence. 
Typically, small-molecules ligands that bind G4s are tested by 
melting experiments (FRET-melting) for their ability to stabilise 
G4-structures.14 Even though stabilisation properties are 
correlated, on some level, to the binding affinity of the ligands, 
they cannot be considered a direct affinity measurement and 
are difficult to apply to peptides that are temperature sensitive. 
To overcome this limitation, we decided to exploit the higher 
molecular weight of the 22-amino acid peptide, compared to small-
molecules, to develop a Fluorescence-Polarisation (FP) assay to 
reliably measure G4-binding. The FP measurements rely on the use 
of a fluorescein (FAM) labelled oligonucleotide and the formation of 
a big complex (peptide-DNA) upon binding. The peptide-DNA 
complex formation causes a slower tumbling of the FAM-labelled 
oligonucleotide, which in turn generates a fluorescence polarised 
signal that can be detected as a function of the fraction of the 
oligonucleotide bound to the peptide.15 We initially applied our FP-
assay to evaluate the binding affinity of DM039 to MYC G4. As 
displayed in Figure 2, DM039 binds with high affinity to MYC G4 with 
an observed Kd of 112 nM [59-196 nM - 95% CI], confirming the 
suitability of our FP-assay to measure binding affinity of short 
peptides to G4s. We next tested whether the high binding affinity of 
DM039 to MYC was specific to G4-folded oligonucleotides, testing its 
binding by FP to a FAM-labelled single stranded mutant of MYC, no 
longer able to fold into a G4, and to a FAM-labelled double-stranded 
DNA sequence (see ESI). DM039 displayed negligible binding to both 
the MYC-mutant and double-stranded DNA controls, suggesting that 
G4-specific interactions are responsible for the observed binding to 
the MYC G4. To further test that the binding to MYC was dependent 
on the G4-folding status, we measured reduced binding affinity of 
DM039 to the MYC G4 sequence when annealed in Li+ buffer, which 
prevents stabilisation of the formed G4. The resulting Kd was 1226 
nM [491-3469 nM – 95% CI], proving a ~ 10-fold reduction in binding 
affinity with respect to the binding event in K+ buffer (see ESI).
Since previous reports on similar peptide sequences suggested 
selectivity for parallel G4s over antiparallel ones,13 we decided 
to test the binding affinity of DM039 to other parallel G4s. 
Specifically, we have tested FP-binding of DM039 to FAM-
labelled c-KIT1 and c-KIT2 G4s, which are known to fold into a 
parallel topology.16 Surprisingly, DM039 showed negligible 
binding to both c-KIT1 and c-KIT2 G4s (see ESI), suggesting that 
this particular peptide sequence is not selective to all parallel 
conformations but can strongly discriminate against G4s of the 
same topology. 
We further investigated whether DM039 was unable to bind 
non-parallel G4s, as reported for similar peptide sequences 
extracted from human DHX36.13 To this end, we performed the 
FP-assay against FAM-labelled HRAS G4 (antiparallel),17  hTelo18 
and BCL-219 G4s (mixed type). DM039 displayed negligible 
binding to either HRAS or hTelo G4s, confirming the inability of 
this peptide to bind some non-parallel G4-structures that was 
previously reported (see ESI).13 On the other hand, the DNA G4 
found in the promoter region of the BCL-2 oncogene, which also 
folds into a mixed-type conformation,19 was bound by DM039 
with an observed Kd of 579 nM [447-749 nM - 95% CI]. Although 
the binding affinity is lower to what observed for MYC G4 (~5 
fold), this evidence suggested that DM039 could interact with 
some non-parallel G4s, possibly due to an unusually high 
accessibility of the G-tetrads in this mixed-type structure.
We next sought to confirm the high binding affinity displayed by 
DM039 to MYC G4 using a fluorescent independent Surface 
Plasmon Resonance (SPR) to measure the dissociation constant 
Figure 2: FP binding traces obtained with DM039 in the 
presence of c-MYC (black) and BCL-2 (red). The FP 
experiments were performed in Inner cell buffer (see ESI), at 
room temperature, by using a fixed concentration of 
oligomer (20 nM) and increasing concentrations of peptide 
(0-5000 nM. Here, only the range 0-1500 nM is shown) (see 
ESI). Each measurement was repeated three times.
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of DM039 bound to MYC G4. Strikingly, SPR data confirmed high 
binding affinity of DM039 to MYC G4, providing a measured Kd 
of 123 ± 23 nM (Figure 3), which is in excellent agreement with 
the values obtained by FP.
Figure 3: SPR experiments to study the interaction of DM039 
and MYC G4 where the ligand concentration was varied from 
0.1 nM to 10 µM.
Altogether, our biophysical study revealed that the DM039 
peptide preferentially binds MYC G4 with high selectivity over 
single-stranded and double-stranded DNA. Furthermore, 
DM039 displayed a significant degree of intra-G4 selectivity 
that, in contrast with previous reports, is not simply dictated by 
G4-topology but rather dependent on specific G4-structural 
features. This suggests that peptide-based binding of G4s might 
be the key to achieve individual G4-targeting by means of 
molecular probes.
The 22-amino acid sequence that constitutes DM039 is folded 
into a -helix in the crystal structure reported of bovine DHX36 
bound to MYC G4.11 To test whether DM039 also adopts an 
helical conformation when bound to MYC, we have performed 
CD analysis of DM039 in solution and in the presence of MYC G4 
(see ESI). Whilst DM039 appear to be unstructured in solution, 
an -helical CD signal becomes detectable upon binding of the 
peptide to MYC G4, displaying an increase in the calculated 
helical fraction (fH) from 0.073 measured with DM039 in 
solution to 0.155 observed upon MYC binding (see ESI). 
Therefore, we wanted to investigate whether conformationally 
constraining the wild type peptide using a hydrocarbon staple 
could pay the entropic penalty of folding and improve the 
binding affinity of DM039 to MYC G4.
To test this hypothesis, we designed two stapled peptide 
analogues of the wild type peptide, DM083 (i, i+4 type staple) 
and DM102 (i, i+7 type staple) (Figure 4A and B). On inspection 
of the helical interaction motif of bovine DHX36 bound to MYC 
G4 in the crystal structure and using the helix wheel, there are 
two ideal positions on the back face of the helix with which to 
incorporate a conformational constraint. The i,i+4 stapled 
peptide DM083 was designed to incorporate the hydrocarbon 
bridge across one loop of the helix between residues K71 and 
Q75 (Figure 4A). A longer i,i+7 hydrocarbon constrain was also 
designed that constrains across two loops of the helix, between 
residues E64 and K71 (Figure 4B). Importantly, the residues 
mutated do not appear to take part in the binding event with 
MYC G4 or intramolecular stabilising interactions. The linear 
peptides were synthesised using standard Fmoc/tBu SPPS 
conditions using a microwave assisted peptide synthesiser. 
Commercially available Fmoc-S5-OH and Fmoc-R8-OH were used 
to incorporate the nonproteinogenic amino acids with the 
appropriate alkene functionality required for ring-closing 
metathesis, which was achieved using Grubbs 1st Generation 
Catalyst. The resulting cyclised peptides were cleaved from solid 
support and globally deprotected under standard acidic 
conditions (TFA/TIS/H2O). The crude peptides were then 
purified by RP-HPLC and characterised using analytical RP-HPLC 
and mass spectrometry (ESI) (see ESI).
We first validated that stapling increased the helicity of the 
peptides by CD, observing a fH of 0.18 and 0.22 for DM083 and 
DM102 respectively (see ESI). Crucially, the fH values of both 
DM083 and DM102 did not increase in the presence of MYC G4 
(see ESI). The two stapled peptides were then assessed for 
Figure 4: A) i,i+4 hydrocarbon stapled peptide DM083, B) i,i+7 
hydrocarbon stapled peptide DM102 C) Differential binding 
behaviour against MYC G4 observed for DM039 and its two 
stapled versions (DM083 and DM102) by means of FP 
measurements. The FP experiments were performed in Inner 
cell buffer (see ESI), at room temperature, by using a fixed 
concentration of oligomer (20 nM) and increasing 
concentrations of peptide (0-5000 nM) (see ESI). Each 
measurement was repeated three times.
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binding to MYC G4 by means of our FP-assay. Both DM083 and 
DM102 displayed a significant reduction of binding affinity to 
MYC G4, with measured Kd of 548 nM [317-934 nM - 95% CI] 
and 332 nM [249-435 nM - 95% CI] respectively (Figure 4C). This 
suggested that stabilising the helical peptide conformation 
reduces the affinity for the targeted G4-structure (see ESI). 
Whilst i,i+4 stapling in DM083 reduces binding affinity to MYC 
G4 of ~5 fold, i,i+7 stapled peptide DM102 still retains 
substantial binding affinity to MYC G4 with a reduction of ~3 
fold compared to DM039. This is in agreement with a recent 
report that revealed how lactam stapling of a similar peptide 
sequence overall retained G4-binding ability.20 Nevertheless, 
we wanted to evaluate whether chemically locking of the 
peptide into a helical conformation, observed in the DHX36 
crystal structure, resulted in retention of preferential selectivity 
for MYC G4, since the DHX36 helicase, unlike DM039, does not 
display intrinsic selectivity for a specific G4-structure or 
topology. We therefore tested the i,i+7 stapled peptide DM102 
for binding to parallel and non-parallel DNA G4s as well as to 
single and double-stranded DNA controls. Surprisingly, we 
observed that DM102 binds with similar binding affinities all the 
oligonucleotide tested, yielding observed Kd values of 574 nM 
[381-855 nM - 95% CI] for c-KIT1, 1081 nM [847-1383 nM - 95% 
CI] for hTelo, 831 nM [622-1112 nM - 95% CI] for BCL-2, 1238 
nM [827-1878 nM - 95% CI] for HRAS, 2628 nM [1648-4497 nM 
- 95% CI] for MYC-mutant and 2377 nM [1440-4222 nM - 95% 
CI] for double-stranded DNA. This observation suggested that 
DM039 binds to MYC G4 through an induced fit mechanism (see 
ESI) and a good degree of flexibility is required of the extended 
peptide backbone for both high affinity interaction and 
selectivity, as chemical stapling of this sequence in DM102 
rendered the peptide a non-specific DNA binder. 
In conclusion, we have developed a FP-assay to measure 
binding affinity of a short peptide (22 amino acids) extracted 
from a crystal structure of the bovine DHX36 helicase bound to 
MYC G4. Although selectivity towards parallel G4-topologies 
was previously suggested for similar peptide sequences, we 
report that the particular peptide used in this work displays 
negligible binding to other parallel G4-structures (c-KIT1 and c-
KIT2), binding to a mixed type G4 (BCL-2) and a preferential 
binding to MYC G4. Furthermore, we observed that chemical 
stapling of this peptide might preserve MYC binding but 
abrogates intra-G4 selectivity as well as selectivity over single 
and double-stranded DNA, suggesting that a rigid, extended 
peptide -helical conformation is detrimental to the observed 
MYC selectivity. We anticipate that further investigation on 
DM039 binding modes and non-canonical chemical stapling will 
be key to develop a MYC-selective probe and disentangle the 
biological role of this particular G4 over the ~700,000 present in 
the human genome. Our findings might pave the way towards 
the rational design of peptide-based molecular probes for 
selective targeting of individual G4s.
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